PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.
The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration
Continue reading “Another PARP inhibitor showing promise”
The above is an abbreviation of the title of a New England Journal of Medicine (N Engl J Med 2017; 376:2286-91), in this article, the authors discuss identification of a group of tumors that are composed of predominantly overdiagnosed tumors. In order to be clear, I have to start with few definitions.
Overdiagnosis refer to tumors dectected on screening that never would have led to clinical symptoms.
Continue reading “Small tumors are good, or good tumors are small?”